{
  "research_date": "2026-02-11",
  "intervention_name": "SkeetSteph",
  "intervention_type": "drug",

  "regulatory_pathway": {
    "recommended_pathway": "NDA (New Drug Application) - 505(b)(1)",
    "rationale": "SkeetSteph is a novel GLP-1 receptor agonist (new chemical entity/NCE) requiring full NDA submission with complete clinical data package. Not a generic (ANDA) or modified existing product (505(b)(2)).",
    "regulatory_classification": {
      "novelty": "New Chemical Entity (NCE)",
      "product_type": "Small molecule or peptide (GLP-1 receptor agonist)",
      "rx_status": "Prescription only",
      "controlled_substance": false
    },
    "ind_requirements": {
      "ind_required": true,
      "cfr_reference": "21 CFR 312",
      "submission_strategy": "Standard IND submission with 30-day FDA review period before Phase 1 initiation",
      "pre_ind_meeting": "Type B Pre-IND meeting strongly recommended to align on clinical development plan, nonclinical requirements, and CMC strategy",
      "clinical_hold_risk_factors": [
        "Alopecia safety signal requires proactive monitoring plan",
        "Standard GLP-1 class concerns (pancreatitis, thyroid C-cell tumors, gallbladder events)",
        "Ensure adequate nonclinical toxicology package including carcinogenicity studies (2-year rodent)"
      ]
    },
    "ich_guidelines": [
      "ICH E6(R2) - Good Clinical Practice",
      "ICH E9(R1) - Statistical Principles including Estimand Framework",
      "ICH E10 - Choice of Control Group",
      "ICH E1 - Safety database size (chronic use: ≥1500 patients exposed ≥6 months, ≥500 exposed ≥1 year)",
      "ICH S7A/S7B - Safety Pharmacology",
      "ICH S9 - Nonclinical Evaluation"
    ],
    "key_fda_guidance": {
      "title": "Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction (Draft, January 2025)",
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/obesity-and-overweight-developing-drugs-and-biological-products-weight-reduction",
      "key_requirements": [
        "Primary endpoint: continuous weight change variable (% change from baseline)",
        "Responder analyses at ≥5%, ≥10%, ≥15% weight reduction thresholds",
        "≥3,000 subjects randomized to investigational drug at recommended dose",
        "≥1,500 subjects on placebo for ≥1 year maintenance treatment",
        "Population: BMI ≥30 or BMI ≥27 with ≥1 weight-related comorbidity",
        "Must include representative sampling of Class 3 obesity (BMI ≥40)",
        "Standard-of-care diet and physical activity applicable to primary care",
        "At least 1 Phase 3 trial with structured lifestyle intervention",
        "Maintenance period ≥1 year on maintenance dosing",
        "Multiple imputation methodology (not LOCF) for missing data",
        "Estimand framework addressing intercurrent events (treatment discontinuation)",
        "Diversity plans including comorbidities (CV disease, heart failure, liver disease, CKD)",
        "Clinical outcome assessments (COAs) as secondary endpoints for labeling claims",
        "Dedicated trial or powered sub-study for Type 2 diabetes population",
        "Pediatric investigation plan due ≤60 days post-Phase 2 meeting (ages 6+)"
      ]
    }
  },

  "similar_trials": [
    {
      "rank": 1,
      "nct_id": "NCT03548935",
      "trial_name": "STEP 1",
      "drug": "Semaglutide 2.4 mg (Wegovy)",
      "sponsor": "Novo Nordisk",
      "phase": "Phase 3",
      "status": "Completed",
      "sample_size": 1961,
      "randomization": "2:1 (drug:placebo)",
      "design": "Randomized, double-blind, placebo-controlled",
      "population": "Adults BMI ≥30 or ≥27 with comorbidity, without diabetes",
      "duration": "68 weeks",
      "primary_endpoints": ["Percentage change in body weight from baseline", "Weight reduction ≥5%"],
      "key_results": "14.9% mean weight loss vs 2.4% placebo",
      "relevance": "Most directly comparable — same drug class, same population, pivotal approval trial"
    },
    {
      "rank": 2,
      "nct_id": "NCT04184622",
      "trial_name": "SURMOUNT-1",
      "drug": "Tirzepatide 5/10/15 mg (Zepbound)",
      "sponsor": "Eli Lilly",
      "phase": "Phase 3",
      "status": "Completed",
      "sample_size": 2539,
      "randomization": "1:1:1:1 (5mg:10mg:15mg:placebo)",
      "design": "Randomized, double-blind, placebo-controlled, multicenter",
      "population": "Adults BMI ≥30 or ≥27 with ≥1 comorbidity, without diabetes",
      "duration": "72 weeks (including 20-week dose escalation)",
      "primary_endpoints": ["Percentage change in body weight from baseline", "Weight reduction ≥5%"],
      "key_results": "15.0% (5mg), 19.5% (10mg), 20.9% (15mg) mean weight loss vs 3.1% placebo; 85-91% achieved ≥5% loss",
      "relevance": "Gold standard Phase 3 design for weight management; demonstrates multi-dose approach"
    },
    {
      "rank": 3,
      "nct_id": "NCT05646706",
      "trial_name": "STEP UP",
      "drug": "Semaglutide 7.2 mg",
      "sponsor": "Novo Nordisk",
      "phase": "Phase 3b",
      "status": "Completed",
      "sample_size": 1407,
      "randomization": "Multiple arms (7.2mg vs 2.4mg vs placebo)",
      "design": "Randomized, double-blind, parallel-group, placebo-controlled",
      "population": "Adults BMI ≥30, without diabetes",
      "duration": "72 weeks",
      "primary_endpoints": ["Superiority of semaglutide 7.2mg vs placebo in weight loss"],
      "key_results": "Higher dose semaglutide showed superior weight loss vs 2.4mg and placebo",
      "relevance": "Most recent large GLP-1 trial; demonstrates dose-response for higher GLP-1 doses"
    },
    {
      "rank": 4,
      "nct_id": "NCT05869903",
      "trial_name": "ATTAIN-1",
      "drug": "Orforglipron 6/12/36 mg (oral small molecule GLP-1 RA)",
      "sponsor": "Eli Lilly",
      "phase": "Phase 3",
      "status": "Completed",
      "sample_size": 3127,
      "randomization": "Multiple arms (6mg, 12mg, 36mg, placebo)",
      "design": "Multinational, randomized, double-blind, placebo-controlled",
      "population": "Adults with obesity without diabetes",
      "duration": "72 weeks",
      "primary_endpoints": ["Mean body weight reduction"],
      "key_results": "7.5% to 11.2% weight loss vs 2.1% placebo across dose groups",
      "relevance": "Latest Phase 3 GLP-1 RA; large sample size aligned with 2025 FDA guidance"
    },
    {
      "rank": 5,
      "nct_id": "NCT05564117",
      "trial_name": "OASIS 4",
      "drug": "Oral semaglutide 25 mg",
      "sponsor": "Novo Nordisk",
      "phase": "Phase 3",
      "status": "Completed",
      "sample_size": 307,
      "randomization": "Drug vs placebo",
      "design": "Randomized, double-blind, placebo-controlled",
      "population": "Adults with obesity or overweight with ≥1 comorbidity",
      "duration": "64 weeks",
      "primary_endpoints": ["Percentage change in body weight"],
      "key_results": "16.6% mean weight loss",
      "relevance": "Supports oral formulation approach; relatively smaller trial supported approval"
    },
    {
      "rank": 6,
      "nct_id": "NCT05813795",
      "trial_name": "Ecnoglutide Phase 3",
      "drug": "Ecnoglutide (biased GLP-1 RA)",
      "sponsor": "Various",
      "phase": "Phase 3",
      "status": "Completed",
      "sample_size": null,
      "randomization": "Drug vs placebo",
      "design": "Randomized, double-blind, placebo-controlled, multicenter",
      "population": "Adults 18-75 years, overweight or obesity without diabetes",
      "duration": "Not specified",
      "primary_endpoints": ["Weight reduction efficacy"],
      "key_results": "Demonstrated efficacy in Chinese population",
      "relevance": "Novel biased GLP-1 RA; shows expanding competitive landscape"
    }
  ],

  "alopecia_safety_signal": {
    "summary": "Alopecia is an emerging adverse effect associated with GLP-1 receptor agonists for weight loss. Over 1,000 spontaneous cases reported in FDA FAERS database.",
    "reporting_odds_ratios": {
      "semaglutide": "ROR 2.46 (95% CI: 2.14-2.83)",
      "tirzepatide": "ROR 1.73 (95% CI: 1.42-2.09)"
    },
    "types_reported": [
      "Telogen effluvium (most common — diffuse hair shedding from metabolic stress of rapid weight loss)",
      "Androgenic alopecia",
      "Alopecia (unspecified)",
      "Central centrifugal cicatricial alopecia",
      "Folliculitis decalvans"
    ],
    "proposed_mechanisms": [
      "Rapid weight loss inducing telogen effluvium via metabolic stress",
      "Nutritional deficiencies from caloric restriction disrupting hair growth cycle",
      "Direct GLP-1 receptor effects on hair follicle cells (under investigation)"
    ],
    "protocol_implications": [
      "Include standardized alopecia grading scale (e.g., CTCAE v5.0 or Severity of Alopecia Tool - SALT)",
      "Require baseline and serial hair assessments at key timepoints",
      "Include alopecia as a prespecified adverse event of special interest (AESI)",
      "Collect hair density/photographic documentation at scheduled visits",
      "Monitor nutritional biomarkers (ferritin, zinc, biotin, vitamin D) at baseline and during treatment",
      "Include patient-reported outcomes for hair loss impact (e.g., Hairdex questionnaire)",
      "Define stopping rules if severe/irreversible alopecia observed"
    ]
  },

  "study_design_recommendations": {
    "suggested_design": "Randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 trial",
    "phase": "Phase 3",
    "rationale": "Consistent with all approved GLP-1 RA weight management programs (STEP, SURMOUNT, ATTAIN, OASIS) and 2025 FDA guidance requirements",
    "comparator": "Placebo (matching subcutaneous injection) + lifestyle intervention (reduced-calorie diet + increased physical activity)",
    "randomization": "2:1 (SkeetSteph : placebo) — maximizes drug exposure data per FDA guidance requiring ≥3000 on drug",
    "blinding": "Double-blind with matching placebo injections",
    "stratification_factors": [
      "BMI category (30-34.9 vs 35-39.9 vs ≥40)",
      "Sex",
      "Race/ethnicity",
      "Glycemic status (normoglycemia vs prediabetes)"
    ],
    "dose_escalation": "20-week dose escalation period (consistent with SURMOUNT-1 and STEP programs) to improve GI tolerability",
    "treatment_duration": "72 weeks total (20-week escalation + 52-week maintenance) consistent with current FDA guidance requiring ≥1 year maintenance",
    "primary_endpoints": [
      "Percent change in body weight from baseline to Week 72",
      "Proportion of participants achieving ≥5% body weight reduction at Week 72"
    ],
    "key_secondary_endpoints": [
      "Proportion achieving ≥10% weight reduction",
      "Proportion achieving ≥15% weight reduction",
      "Change in waist circumference",
      "Change in systolic blood pressure",
      "Change in fasting glucose and HbA1c",
      "Change in lipid panel (LDL-C, HDL-C, triglycerides)",
      "Incidence and severity of alopecia (AESI)",
      "Patient-reported outcomes (IWQOL-Lite, SF-36, Hairdex)"
    ],
    "sample_size_considerations": {
      "target_enrollment": "4500 (3000 drug : 1500 placebo per 2:1 randomization)",
      "rationale": "Meets FDA 2025 guidance: ≥3000 on drug, ≥1500 on placebo for ≥1 year. Comparable to ATTAIN-1 (N=3127) and larger than STEP 1 (N=1961) and SURMOUNT-1 (N=2539).",
      "powering": "99%+ power for primary endpoints based on expected ~12-15% weight loss vs ~2-3% placebo (effect sizes from STEP and SURMOUNT programs)"
    },
    "population": {
      "age_range": "30-39 years (per sponsor request; note FDA may request broader age range for generalizability)",
      "bmi_criteria": "BMI ≥30 kg/m²",
      "key_inclusion": [
        "Adults aged 30-39 years",
        "BMI ≥30 kg/m²",
        "Without type 2 diabetes mellitus",
        "Stable body weight (≤5% change in past 3 months)",
        "At least 1 failed weight management effort"
      ],
      "key_exclusion": [
        "Type 1 or Type 2 diabetes mellitus",
        "Prior bariatric surgery",
        "History of pancreatitis",
        "Personal or family history of medullary thyroid carcinoma or MEN2",
        "Active or history of alopecia areata or other autoimmune hair loss",
        "Current use of medications known to cause weight gain or hair loss",
        "Pregnancy, breastfeeding, or planning pregnancy",
        "Severe renal impairment (eGFR <30)",
        "History of suicidal ideation or behavior"
      ]
    }
  },

  "approved_glp1_landscape": [
    {
      "drug": "Semaglutide (Wegovy)",
      "manufacturer": "Novo Nordisk",
      "route": "Subcutaneous injection (2.4mg weekly) and Oral (25mg daily)",
      "approval_year": "2021 (injectable), 2025 (oral)",
      "nda_number": "NDA 215256 (injectable)"
    },
    {
      "drug": "Liraglutide (Saxenda)",
      "manufacturer": "Novo Nordisk",
      "route": "Subcutaneous injection (3.0mg daily)",
      "approval_year": "2014",
      "nda_number": "NDA 206321"
    },
    {
      "drug": "Tirzepatide (Zepbound)",
      "manufacturer": "Eli Lilly",
      "route": "Subcutaneous injection (weekly)",
      "approval_year": "2023",
      "nda_number": "NDA 217806"
    }
  ],

  "key_insights": [
    "All recent GLP-1 weight management trials use randomized, double-blind, placebo-controlled design with 68-72 week duration",
    "Co-primary endpoints of % weight change + ≥5% responder analysis are standard; 2025 FDA guidance emphasizes continuous variable as primary",
    "Sample sizes range from 307 (OASIS 4) to 3127 (ATTAIN-1); FDA 2025 guidance requires ≥3000 on drug + ≥1500 on placebo",
    "Dose escalation periods of 16-20 weeks are standard to manage GI tolerability",
    "Alopecia is a well-documented emerging safety signal with GLP-1 RAs; SkeetSteph protocol should include proactive monitoring as a differentiator",
    "2025 FDA guidance introduces estimand framework and multiple imputation — must be reflected in statistical analysis plan",
    "Lifestyle intervention (diet + exercise counseling) is mandatory in both arms per FDA guidance",
    "FDA may request broader age range than 30-39 for generalizability; consider discussing with FDA in Pre-IND meeting",
    "Pediatric investigation plan required within 60 days of End-of-Phase 2 meeting"
  ]
}